Navigation Links
Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference
Date:4/26/2010

HAYWARD, Calif., April 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer will present at the Deutsche Bank 35th Annual Health Care Conference in Boston, MA on Monday, May 3, 2010 at approximately 9:20 am Eastern Time.  

To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.anthera.com.  Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

CONTACT: Juliane Snowden of Burns McClellan, Inc., jsnowden@burnsmc.com or 212.213.0006.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
2. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
3. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
5. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
11. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted ... expected to grow at a CAGR of 6.0% during ... larger share in the global market between the two ... the hospital segment accounted for the highest share in ... peripheral I.V. catheter market is witnessing high growth rate, ...
(Date:1/23/2017)... Jan. 23, 2017  HOPE BIOSCIENCES announced today ... develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through ... pharmaceutical company. nuc -Gemcitabine consists ... surface nucleolin found on many cancer cells, and ... (antibody drug conjugates) or SMDCs (small molecule drug ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American ... particularly good news for prostate cancer patients: incidents of cancer is down as is ... report the cancer death rate has dropped from its peak of 215.1 in 1991 ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... officially unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience ... Taza Agua is renowned for introducing the world’s first untouched bottled water purposed ...
(Date:1/24/2017)... ... 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an ... gossip, prostitution, adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” ... David Coats. In September of 1983, they flew to Haiti to focus on ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... “The Octagon ... balance. “The Octagon of Spiritual Balances” is the creation of published author, Pastor Bernard ... Bernard J. Weathers holds a bachelor degree in religious education and a master degree ...
Breaking Medicine News(10 mins):